Platelet-rich plasma (PRP) is presently employed across various medical disciplines, including surgical specialties. It is primarily used in the healing of chronic wounds, burn medicine, tissue regeneration support, and scar correction as well as in other surgical and orthopedic indications. Wounds, in general, possess a pro-inflammatory biochemical environment characterized by high protease activity that diminishes the effective concentration of growth factors. In contrast, PRP serves as a source of growth factors and exhibits mitogenic, angiogenic, and chemotactic properties. PRP is a biological product defined as a portion of the autologous blood's plasma fraction with a higher than physiological platelet concentration. PRP is obtained through the centrifugation of blood samples collected from patients. The insights into the biology, mechanism of action, and classification of PRP presented in this review can assist medical professionals in orienting themselves and comprehending the possibilities of the clinical application of this therapy, which remains a subject of investigation and validation. This review summarizes up-to-date information regarding the use of PRP, primarily in burn and reconstructive surgery, plastic surgery, traumatology, and general surgery.
- MeSH
- hojení ran * fyziologie MeSH
- lidé MeSH
- plazma bohatá na destičky * MeSH
- popálení chirurgie krev MeSH
- zákroky plastické chirurgie metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Klíčová slova
- sysadoa,
- MeSH
- antiflogistika nesteroidní aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- hormony kůry nadledvin aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- kolagen aplikace a dávkování terapeutické užití MeSH
- konzervativní terapie MeSH
- kyselina hyaluronová aplikace a dávkování terapeutické užití MeSH
- lidé MeSH
- osteoartróza * diagnóza patofyziologie terapie MeSH
- plazma bohatá na destičky MeSH
- rehabilitace MeSH
- viskosuplementace MeSH
- Check Tag
- lidé MeSH
Background: The knee is the predominant weight-bearing joint affected by osteoarthritis, and knee osteoarthritis (KOA) is the 11th significant cause of disability. As life expectancy has increased, the need for knee replacement procedures has grown, putting a major financial burden on patients and healthcare systems. Intra-articular (IA) injection of platelet rich plasma (PRP) promises to be a potential method in research for the more preservative and biological strategies to treat this chronic degenerative condition. PRP has expected to contain a high number of growth factors and proteins involved in tissue repair mechanisms.Aim: This study aimed to determine the effect of intra-articular injections (IAIs) pure-PRP and their dosage regimen efficacy in patients with mild and moderate knee OA.Material and method: This study included 33 patients (11 male and 22 female). The patient groups included 16 with mild and 17 with moderate knee osteoarthritis. With ages ranged from 32 to 66 years old. These patients were divided into three groups based on dosage (12 received a single injection, 11 received a double injection, and 10 received a triple injection), with a two-week interval between injections. The outcome was measured using WOMAC index for pain, stiffness, and daily functional limitation, as well as laboratory testing for TNF-alpha using the Eliza technique. All the patients were assessed at baseline and after three months of injection. The study was designed as non-randomized controlled trial study during November 2021 to May 2022 at Al-imam Ali hospital, Babylon governorate, Iraq.Results: Regarding severity, In both mild and moderate knee osteoarthritis, serum TNF-alpha was significantly lower after treatment (p < 0.001). All WOMAC scores were showed significantly lower levels after treatment with pure-PRP as compared with their levels before treatment (p ≤ 0.001, Regarding the number of injections, all patients who received a single injection, double injections, and triple injections showed a significant decrease in the serum TNF-alpha and WOMAC scores (p 0.05) in both mild and moderate patients. The triple injections were more effective than double and single injections.Conclusions: In conclusion, the treatment with pure-PRP was safe and satisfactory for patients in terms of relieving clinical symptoms. The WOMAC scores has indicated that improvement in pain relief for patients after injection and could act as an anti-inflammatory, as inflammatory marker TNF-alpha was reduced after injection, and there was a superior outcome to increasing dose numbers, as triple injection gave a positive outcome in both mild and moderate KOA when compared to single and double injection.
- MeSH
- artróza kolenních kloubů * terapie MeSH
- dospělí MeSH
- injekce intraartikulární MeSH
- lidé středního věku MeSH
- lidé MeSH
- plazma bohatá na destičky * MeSH
- statistika jako téma MeSH
- terapeutický index MeSH
- TNF-alfa analýza MeSH
- ukazatele zdravotního stavu MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- klinická studie MeSH
Background: The level of pro-inflammatory Cluster of Differentiation 68 (CD 68) could be beneficial for examination as a biomarker for identifying cartilage or knee tissue degradation in joint problems. Because Cluster of Differentiation 68 appears to be linked to cell damage in the injury area, its measurement may be an effective and sensitive tool for detecting the early development of knee osteoarthritis (KOA) in people at risk for knee osteoarthritis.Aim of the study: The study aimed to evaluate which type of PRP (Pure-PRP and leukocyte-PRP) are suitable for patients with KOA via assessing the levels of serum CD 68 concentration.Materials and Methods: Serum Cluster of Differentiation 68 level was computed using ELISA kits. The experimental study comprises 21 pure-platelet-rich plasma (P-PRP) injections,11 leukocytes platelet-rich plasma (L-PRP) injections, and 16 control groups. Ranged from 35- 75 years old. All patients with diabetes mellitus, autoimmune disease, and severe knee osteoarthritis were excluded from this study. The period of the study was between November 2021 to June 2022. This study assessed other factors such as age, sex, family inheritance, and body mass index (BMI). The level of CD 68 was measured in the serum before and after the injection for six weeks.Results: The level of the study showed CD 68 elevated before injection in patients with knee osteoarthritis. A significant decrease of CD 68 (P< 0.01-P<0.001) in the serum concentration after injection as compared to before injection. However, the concentration was significantly higher than the control.Conclusions: In conclusion, both P-PRP and L-PRP demonstrated anti-inflammatory properties. Patients in both groups experienced a significant decrease in CD 68 serum levels, however, the P-PRP was more effective than the L-PRP.
- MeSH
- artróza kolenních kloubů * imunologie terapie MeSH
- CD antigeny aplikace a dávkování imunologie krev MeSH
- dospělí MeSH
- injekce intraartikulární MeSH
- klinické laboratorní techniky metody přístrojové vybavení MeSH
- lidé středního věku MeSH
- lidé MeSH
- plazma bohatá na destičky * fyziologie imunologie MeSH
- senioři MeSH
- zánět imunologie terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- klinická studie MeSH
BACKGROUND: Previous studies have assessed different aspects concerning the applications of i-PRF in the oral cavity. However, nothing is known regarding patients' perceptions of the injection of autologous platelet-rich fibrin (i-PRF). OBJECTIVES: To investigate patients' perceptions after injecting platelet-rich fibrin (i-PRF) in the course of retracting upper canines. METHODS: Twenty-one patients, whose treatments required extractions of both upper first premolars, were recruited. Extraction side was randomly allocated to the intervention or control sides. After the alignment phase, i-PRF was injected twice with a one-month interval on the buccal and palatal aspects of the extraction sites (intervention side). Patients' perceptions were evaluated with two questionnaires: the first was used to assess the level of pain, discomfort, swelling, eating and swallowing difficulties as well as jaw movement restriction after 1 h (T1), 2 h (T2), 6 h (T3), 24 h (T4) and 48 h (T5) of the second injection; the second questionnaire was used to assess the acceptance of the i-PRF injection and overall satisfaction with this technique at the end of canine retraction phase. Visual Analogue Scale (VAS) was adopted for this purpose. Wilcoxon Signed Rank Test was used to compare between both sides at all time points while Friedman's Test was the selected test for detecting variables' changes over time. Post-hoc Wilcoxon Matched-Pairs Signed-Rank Tests were applied when any of the results were significant. As to the multiplicity of tests, Bonferroni Correction was implemented. RESULTS: Pain and swelling levels were significantly higher on the experimental compared to the control sides at T1, T2, and T3 (P < 0.05), whereas they declined sharply and went back to almost normal values at T4 (after 24 h). At T5 they were 0. Discomfort and difficulty in mastication on intervention sides were significant only at T1 and T2. Pain, swelling, and chewing difficulties were significant (P < 0.001) during the 4 assessed time points. The increase was insignificant regarding swallowing difficulties and jaw movement limitations at all time intervals. CONCLUSIONS: Injecting autologous (i-PRF) during orthodontic canine retraction is a well-perceived and well-tolerated method due to the limited discomfort which significantly diminishes 24 h afterwards. TRIAL'S REGISTRATION: ClinicalTrials.gov (Identifier Number: NCT03399422. 16/01/2018).
Background: Cartilage intermediate layer protein 2 (CILP2) is a monomeric glycoprotein that is mostly expressed in the intermediate zone of articular cartilage and can be detected in the extracellular matrix (ECM). The level of CILP2 in serum and its quantity on the articular cartilage surface and throughout the articular cartilage indicates the potential utility of CILP2 for investigation as a biomarker for determining cartilage deterioration in joint disorders. The CILP2 measurement of changes in cartilage biomarkers may be an effective and sensitive tool for detecting the early development of knee osteoarthritis (KOA) in people at risk for KOA. Changes in CILP2 levels may be beneficial for the early diagnosis of KOA, as CILP2 appears to be linked to cartilage thickness reduction in people who are more likely to develop KOA. Platelet rich plasma (PRP) effectiveness of transforming growth factor, platelet-derived growth factor, and the vascular endothelial growth factor is thought to be related to their release. Because of their capacity to increase matrix formation,growth factors have been widely researched for OA and cartilage regeneration. Hyaluronic acid (HA) is a glycosaminoglycan polymer composed of N-acetyl glucosamine and D-glucuronic acid disaccharide molecules. Early embryonic development, inflammatory, wound repair, cell differentiation, and viscoelasticity are all affected by HA, and other biological processes The study was aimed to evaluate effecte of CILP2 levels after intraarticular injecting pure platelet-rich plasma and hyaluronic acid into patients with early knee osteoarthritis.Materials and Methods: BT LAB kits were used to assess the serum CILP2 level. The experimental investigation included 18 control groups, 10 HA injections, and 21 pure PRP injections. age ranged from 35 to 75. The study was exluded all individuals with advanced osteoarthritis in the knee, COVID-19, diabetes, and autoimmune diseases. the time frame running from November 2021 until June 2022. Other variables in our research were age, gender, family history, use of antihypertensive medications or medications for other disorders, and body mass index (BMI). Results: The findings of this study demonstrate elevated CILP2 levels in patients with early KOA before treatments injection compared with the healthy control. After treatments injection, the level of CILP2 was decreased compared with before injection.
- Klíčová slova
- CILP2,
- MeSH
- artróza kolenních kloubů * farmakoterapie patologie diagnóza MeSH
- časná diagnóza MeSH
- extracelulární matrix - proteiny analýza MeSH
- injekce intraartikulární metody MeSH
- kloubní chrupavka patologie MeSH
- kyselina hyaluronová aplikace a dávkování terapeutické užití MeSH
- lidé MeSH
- osteoartróza patologie MeSH
- plazma bohatá na destičky MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- klinické zkoušky MeSH
New studies have shown the great potential of the combination of in situ enzymatically cross-linked hydrogels based on tyramine derivative of hyaluronic acid (HA-TA) with platelet-rich plasma (PRP) and platelet lysate in regenerative medicine. This study describes how the presence of PRP and platelet lysate affects the kinetics of gelation, viscoelastic properties, swelling ratio, and the network structure of HA-TA hydrogels and how the encapsulation of PRP in hydrogels affects the bioactivity of released PRP determined as the ability to induce cell proliferation. The properties of hydrogels were tuned by a degree of substitution and concentration of HA-TA derivatives. The addition of platelet derivatives to the reaction mixture slowed down the cross-linking reaction and reduced elastic modulus (G') and thus cross-linking efficiency. However, low-swellable hydrogels (7-190%) suitable for soft tissue engineering with G' 200-1800 Pa were prepared with a gelation time within 1 min. It was confirmed that tested cross-linking reaction conditions are suitable for PRP incorporation because the total bioactivity level of PRP released from HA-TA hydrogels was ≥87% and HA-TA content in the hydrogels and thus mesh size (285-482 nm) has no significant effect on the bioactivity level of released PRP.
Osteoarthritisis a highly prevalent musculoskeletal disorder characterized by degradation of cartilage and synovial fluid (SF). Platelet derivatives as platelet-rich plasma (PRP) and platelet lysate have great potential in the treatment of osteoarthritis because they contain biologically active substances including growth factors (GFs). Rapid release of GFs and their short biological half-life are factors that can limit the therapeutic impact of PRP therapy. Herein, the first work that describes hydrogels based on polyaldehyde derivative of hyaluronic acid (HA-OX) as carriers of platelet derivatives for in situ applications is presented, which can be a possible solution to the problem. HA-OX hydrogels containing 50% (w/w) of PRP or platelet lysate can be injected using a syringe due to low viscosity(<10 Pa s) and injection force (<20 N), and reach elastic modulus up to 2000 Pa. Insulin-like GF-1 and Platelet-derived GF-AB release from HA-OX hydrogels (mesh size 297-406 nm) by Fickian and non-Fickian diffusion respectively. The released PRP GFs maintain their ability to induce cell proliferation (87%-92%). Based on the obtained results, the unique concept of a new material that can restore viscoelastic properties of SF and at the same time gradually deliver GFs from platelet derivatives is designed.
Diabetes mellitus is a condition of continuously increased blood glucose levels that causes hyperglycemia. This condition can result in disorders of various organs including testicular problems. The use of platelet-rich plasma (PRP) which is contained in several growth factors shows its potential in overcoming testicular problems. This literature review study was conducted to identify the potential of PRP in overcoming various testicular problems due to diabetic conditions.
- MeSH
- diabetes mellitus * terapie metabolismus MeSH
- hyperglykemie * metabolismus MeSH
- lidé MeSH
- mezibuněčné signální peptidy a proteiny metabolismus MeSH
- plazma bohatá na destičky * metabolismus MeSH
- testis MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Androgenní alopecie je běžná porucha vypadávání vlasů způsobená genetickými a hormonálními faktory, které jsou charakterizovány androgenem souvisejícím progresivním řídnutím vlasů kštice v definovaném vzoru. Terapií první linie androgenní alopecie je topický minoxidil, ale vzhledem k jeho omezenému účinku se plazma bohatá na destičky (PRP) stala účinnou alternativní léčebnou metodou. V kazuistice je popsán případ 35letého muže s androgenní alopecií léčeného lokálně minoxidilem po dobu 3 let s minimálními výsledky. Po 2 aplikacích léčby PRP v kombinaci topickým minoxidilem a topickým finasteridem byl pozorován významný růst během 3 měsíců. Tato kombinovaná léčba se u tohoto pacienta ukázala významně účinnější v léčbě androgenní alopecie než samotný topický minoxidil.
Androgenic alopecia is a common hair loss disorder caused by genetic and hormonal factors that are characterized by androgen-related progressive thinning of scalp hair in a defined pattern. First-line therapy for androgenic alopecia is topical minoxidil but due to its limited effect platelet-rich plasma (PRP) has become an effective alternative treatment. This case study presents a 35 year old male with androgenic alopecia treated with topical minoxidil for 3 years with minimal results. After 2 applications of PRP treatment with concomitant topical minoxidil and topical finasteride significant regrowth was seen within 3 months. This combined treatment proved significantly more effective in the treatment of androgenic alopecia than topical minoxidil alone in this patient.
- MeSH
- alopecie * terapie MeSH
- dospělí MeSH
- finasterid terapeutické užití MeSH
- lidé MeSH
- plazma bohatá na destičky MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
- přehledy MeSH
